State Street SPDR S&P Pharmaceuticals ETF (XPH)
| Assets | $327.37M |
| Expense Ratio | 0.35% |
| PE Ratio | 16.73 |
| Shares Out | 5.70M |
| Dividend (ttm) | $0.46 |
| Dividend Yield | 0.81% |
| Ex-Dividend Date | Dec 22, 2025 |
| Payout Ratio | 13.56% |
| 1-Year Return | +29.41% |
| Volume | 84,461 |
| Open | 57.53 |
| Previous Close | 58.25 |
| Day's Range | 57.04 - 57.87 |
| 52-Week Low | 35.22 |
| 52-Week High | 58.84 |
| Beta | 0.58 |
| Holdings | 59 |
| Inception Date | Jun 19, 2006 |
About XPH
Fund Home PageThe State Street SPDR S&P Pharmaceuticals ETF (XPH) is an exchange-traded fund that is based on the S&P Pharmaceuticals Select Industry index. The fund tracks an equal-weighted index of US pharmaceutical companies. XPH was launched on Jun 19, 2006 and is issued by State Street.
Top 10 Holdings
22.84% of assets| Name | Symbol | Weight |
|---|---|---|
| Definium Therapeutics, Inc. | DFTX | 2.55% |
| Viatris Inc. | VTRS | 2.40% |
| Phibro Animal Health Corporation | PAHC | 2.33% |
| Edgewise Therapeutics, Inc. | EWTX | 2.29% |
| Elanco Animal Health Incorporated | ELAN | 2.25% |
| Merck & Co., Inc. | MRK | 2.24% |
| MBX Biosciences, Inc. | MBX | 2.22% |
| Supernus Pharmaceuticals, Inc. | SUPN | 2.21% |
| Bristol-Myers Squibb Company | BMY | 2.18% |
| Amneal Pharmaceuticals, Inc. | AMRX | 2.17% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 22, 2025 | $0.11302 | Dec 24, 2025 |
| Sep 22, 2025 | $0.10263 | Sep 24, 2025 |
| Jun 23, 2025 | $0.09587 | Jun 25, 2025 |
| Mar 24, 2025 | $0.15332 | Mar 26, 2025 |
| Dec 23, 2024 | $0.15484 | Dec 26, 2024 |
| Sep 23, 2024 | $0.19471 | Sep 25, 2024 |
News
Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More
Big Pharma delivered strong Q4 2025 results, with most companies beating revenue and EPS expectations and providing generally solid 2026 guidance. Eli Lilly solidified its leadership in obesity and di...
XPH: Healthcare Dashboard For January
Healthcare providers have a good value score, and the pharmaceuticals & biotechnology subsector has a good quality score. State Street SPDR S&P Pharmaceuticals ETF provides modified equal-weighted exp...
Why Health Care ETFs Aren't Panicking Over Big Pharma's Price Cuts
As big pharmaceutical companies are set to finalize a deal with the U.S. government to bring down prices for some prescription drugs, another old question is coming into focus for investors: how much ...
Britain will spend more on new medicines in exchange for avoiding tariffs on U.K. pharmaceutical exports to the U.S.
The move marks a victory for the Trump administration's campaign to get other countries to pay more for drugs.
US and UK agree zero-tariffs on pharmaceuticals
The US has agreed to spare the UK from threatened trade tariffs on pharmaceutical products.
UK and US agree zero-tariff pharmaceuticals deal
Agreement also calls for NHS to increase net price it pays for new medicines by 25%
US, UK to agree to zero tariffs on pharmaceuticals, announcement expected, sources say
Britain and the United States are poised to agree to zero tariffs on pharmaceutical products, with an announcement due at the White House on Monday, according to two sources familiar with the matter.
UK and US poised to agree zero-tariffs deal on pharmaceuticals, The Times says
The UK is poised to agree on a major pharmaceuticals deal with the U.S., which will mean zero import tariffs on pharmaceutical products into the U.S. and lead to an increase in NHS spending on medicin...
Investing In Health Stocks - How Policy Clarity Is Opening Doors
The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discoun...
XPH: Small-Cap Pharma Turns Higher, At Long Last
SPDR S&P Pharmaceuticals ETF is rated a "Buy" due to compelling valuation and improving technical momentum. XPH offers diversified exposure to large-, mid-, and small-cap pharma stocks, balancing blue...
The Trump administration said it isn't planning to impose tariffs on generic drugs from foreign countries, which make up most of medications dispensed in the U.S.
The administration has been weighing duties for months on a range of products and ingredients in a national-security tariff investigation.
Trump Trade War: New Tariffs on Drugs, Trucks, and Furniture Raise Inflation Risks
President Trump's new tariffs on drugs, trucks, and furniture reignite trade tensions, boosting U.S. manufacturers but raising global costs, pressuring exporters, and adding inflation risks.
Drug Tariffs Are a Sideshow. Trump's Next Move Could Hit Pharma Harder.
What unnerves investors is a lack of clarity on drug pricing.
Big Pharma Unfazed by Trump Tariffs, But Small Biotechs Face Vulnerability
Drugmakers have been bracing for levies and sought to get ahead of them with pledges to invest billions more on domestic manufacturing.
Trump announces 100% tariffs on pharmaceutical drugs, beginning October 1
President Donald Trump said Thursday that he will put import taxes of 100% on pharmaceutical drugs, 50% on kitchen cabinets and bathroom vanities, 30% on upholstered furniture and 25% on heavy trucks ...
Pharma stocks gain, as Trump's tariff move actually could be a win for the sector
Pharmaceutical stocks mostly gained Friday, as traders appeared to shrug off or even cheer President Donald Trump's rollout of a new tariff plan for drugmakers.
EU, Japan express confidence in capped US tariffs on drugs
The European Union and Japan expressed confidence on Friday that they had secured limits on U.S. tariffs on pharmaceuticals, which President Donald Trump said he would impose next week at a rate of 10...
India's pharma stock crash after Trump's 100% tariff on branded drugs
India's pharmaceutical stocks were jolted on Friday, when President Donald Trump announced a 100% tariff on imported branded and patented drugs, effective October 1. The move sent shockwaves through g...
Trump announces 100% tariffs on pharmaceuticals unless drug makers are building U.S. factories
President Donald Trump announced a raft of new tariffs late Thursday, including a 100% levy on imported pharmaceuticals unless their manufacturers are actively building factories in the U.S.
Trump announces 100% tariff on imports of branded or patented pharmaceuticals from October 1
The United States will impose a 100% tariff on imports of branded or patented pharmaceutical products from October 1, unless a pharmaceutical company is building a manufacturing plant in the U.S., Pre...
U.S. to impose 100% tariff on branded, patented drugs unless firms build plants locally, Trump says
U.S. to impose 100% tariff on branded, patented drugs unless firms build plants locally, Trump says
Trump hints at higher semiconductor tariffs. Companies could dodge them by doing this.
Trump suggested steep chip-industry tariffs are coming, but there could be breaks for companies that invest in the U.S. Specifics are still sparse.
US FDA announces new program to boost domestic drug manufacturing
The U.S. Food and Drug Administration on Thursday announced a new program to strengthen the domestic pharmaceutical supply chain, by facilitating construction of manufacturing sites in the United Stat...
Trump threatens drugmakers with 250% tariffs. Here's when higher levies could come.
The latest level of tariffs on the pharmaceutical industry is the highest yet from the president.